Matching Items (5)
Description
CD8+ T-lymphocytes (CTLs) are central to the immunologic control of infections and are currently at the forefront of strategies that enhance immune based treatment of a variety of tumors. Effective T-cell based vaccines and immunotherapies fundamentally rely on the interaction of CTLs with peptide-human leukocyte antigen class I (HLA-I) complexes on the infected/malignant cell surface. However, how CTLs are able to respond to antigenic peptides with high specificity is largely unknown. Also unknown, are the different mechanisms underlying tumor immune evasion from CTL-mediated cytotoxicity. In this dissertation, I investigate the immunogenicity and dysfunction of CTLs for the development of novel T-cell therapies. Project 1 explores the biochemical hallmarks associated with HLA-I binding peptides that result in a CTL-immune response. The results reveal amino acid hydrophobicity of T-cell receptor (TCR) contact residues within immunogenic CTL-epitopes as a critical parameter for CTL-self
onself discrimination. Project 2 develops a bioinformatic and experimental methodology for the identification of CTL-epitopes from low frequency T-cells against tumor antigens and chronic viruses. This methodology is employed in Project 3 to identify novel immunogenic CTL-epitopes from human papillomavirus (HPV)-associated head and neck cancer patients. In Project 3, I further study the mechanisms of HPV-specific T-cell dysfunction, and I demonstrate that combination inhibition of Indoleamine 2, 3-dioxygenase (IDO-1) and programmed cell death protein (PD-1) can be a potential immunotherapy against HPV+ head and neck cancers. Lastly, in Project 4, I develop a single-cell assay for high-throughput identification of antigens targeted by CTLs from whole pathogenome libraries. Thus, this dissertation contributes to fundamental T-cell immunobiology by identifying rules of T-cell immunogenicity and dysfunction, as well as to translational immunology by identifying novel CTL-epitopes, and therapeutic targets for T-cell immunotherapy.
onself discrimination. Project 2 develops a bioinformatic and experimental methodology for the identification of CTL-epitopes from low frequency T-cells against tumor antigens and chronic viruses. This methodology is employed in Project 3 to identify novel immunogenic CTL-epitopes from human papillomavirus (HPV)-associated head and neck cancer patients. In Project 3, I further study the mechanisms of HPV-specific T-cell dysfunction, and I demonstrate that combination inhibition of Indoleamine 2, 3-dioxygenase (IDO-1) and programmed cell death protein (PD-1) can be a potential immunotherapy against HPV+ head and neck cancers. Lastly, in Project 4, I develop a single-cell assay for high-throughput identification of antigens targeted by CTLs from whole pathogenome libraries. Thus, this dissertation contributes to fundamental T-cell immunobiology by identifying rules of T-cell immunogenicity and dysfunction, as well as to translational immunology by identifying novel CTL-epitopes, and therapeutic targets for T-cell immunotherapy.
ContributorsKrishna, Sri (Author) / Anderson, Karen S (Thesis advisor) / LaBaer, Joshua (Committee member) / Jacobs, Bertram L (Committee member) / Lake, Douglas F (Committee member) / Arizona State University (Publisher)
Created2017
Description
Adoptive cell therapies such as chimeric antigen receptor (CAR) modified immune cells are revolutionizing cancer treatment. These innovative immunotherapies have a promising outlook for liquid cancers, but lack robustness against solid tumors due to complex variables introduced by the tumor microenvironment (TME). Additionally, existing CAR-T cell treatments are commonly accompanied by toxic side effects. However, by grafting a CAR construct onto macrophages, a professional phagocytic innate cell which are actively recruited by solid tumors, the efficacy of this treatment is hoped to be extended beyond hematological malignancies. Moreover, the introduction of energy metabolite-based polymers (EMPs) to provide a sustained release of activating F16BP-poly(I:C) microparticles could address the toxicity complications that arise from CAR treatments. It was determined that PLGA-F16BP-poly(I:C) microparticles allow for CAR-macrophage activation in vitro, though not in a sustained manner. Moreover, F16BP-poly(I:C) microparticles were better geared toward reducing cytokine related toxicity in vitro, with in vivo results remaining inconclusive. These findings suggest prioritization between macrophage activation or cytokine storm reduction would be required at this time, though additional future studies to explore variables such as CAR-macrophage sensitivity and the positive control could help refine this immunotherapy.
ContributorsHalim, Michelle (Author) / Acharya, Abhinav P (Thesis advisor) / Holloway, Julianne (Committee member) / Khalifehzadeh, Layla (Committee member) / Arizona State University (Publisher)
Created2023
Description
T cells, a component of the adaptive immune system, play an instrumental role in directing immune responses and direct cell killing in response to pathogens and cancers. T cells recognize and signal through the T cell receptor, a protein heterodimer on the surface of T cells. The T cell receptor is a highly variable structure formed via somatic recombination; the structure recognizes peptides presented on the surface of nucleated cells by major histocompatibility complex proteins in a specific receptor-restricted, peptide-restricted manner. This balance between T cell diversity and T cell specificity stands as a barrier to efficacious development of articificial T cell receptors capable of clearing disease. T cell receptors may be tailored to produce pathogen- or cancer-specific immune responses from autologous T cell populations. This necessitates a pipeline for amplification, cloning, and expression of antigen-specific T cell receptors. This study aims to utilize influenza-specific T cell receptor chains from healthy donor T cells to test a model for T cell receptor cloning and expression. This study utilizes Gateway recombination for high-throughput cloning into mammalian expression vectors. This study has successfully amplified and cloned T cell receptor chains from a population of influenza-specific T cells from donor cell transcripts into mammalian cell expression vectors. Additionally, CD8, a coreceptor for the T cell receptor complex, was successfully cloned and inserted into a vector for expression in mammalian cells. Sanger sequencing has confirmed sequences for influenza-specific T cell receptor chains and the CD8 chain. Future application of this project includes expression in mammalian non-T cells to test for efficacy of expression and, ultimately, expression in cytotoxic cells to create lymphocytes capable of antigen-specific recognition and cytolytic killing of cells of interest.
ContributorsVale, Nolan Richard (Author) / Anderson, Karen (Thesis director) / Blattman, Joseph (Committee member) / Department of Psychology (Contributor) / School of Life Sciences (Contributor) / Barrett, The Honors College (Contributor)
Created2019-05
Description
The human body’s immune system utilizes many different cell types, signaling proteins, and receptors to thwart an infectious pathogen from an individual. Adaptive immunity, particularly with CD4+ T cell lymphocytes & the MHC II receptor, was the focus of this paper by creating a custom destination vector plasmid, pFLIiP, which would contain a gateway cloning site and the nucleotides encoding the first 85 amino acids of the invariant chain protein upstream to provide a means of high-throughput antigen screening via the MHC II receptor and peptide processing pathway. The plasmid pFLIiP was successfully created and sequence verified. Both GFP and mCherry fluorescent proteins were inserted into pFLIiP via LR Clonase and successfully transfected into K562 cancer cells. Fluorescent activity read of a flow cytometer in conjunction with the differing pKa values of the two different fluorescent proteins suggested the fusion protein was in-frame and pFLIiP was successfully targeting the protein to the endosome.
ContributorsGrade, Dylan Beck (Author) / Anderson, Karen (Thesis director) / Hogue, Ian (Committee member) / Knappenberger, Mark (Committee member) / School of Life Sciences (Contributor) / Barrett, The Honors College (Contributor)
Created2020-05
Description
The purpose of this project is to analyze the current state of cancer nanomedicine and its challenges. Cancer is the second most deadly illness in the United States after heart disease. Nanomedicine, the use of materials between 1 and 100 nm to for the purpose of addressing healthcare-related problems, is particularly suited for treating it since nanoparticles have properties such as high surface area-to-volume ratios and favorable drug release profiles that make them more suitable for tasks such as consistent drug delivery to tumor tissue. The questions posed are: What are the current nanomedical treatments for cancer? What are the technical, social, and legal challenges related to nanomedical treatments and how can they be overcome? To answer the questions mentioned above, information from several scientific papers on nanomedical treatments for cancer as well as from social science journals was synthesized. Based on the findings, nanomedicine has a wide range of applications for cancer drug delivery, detection, and immunotherapy. The main technical challenge related to nanomedical treatments is navigating through biological barriers such as the mononuclear phagocyte system, the kidney, the blood-brain barrier, and the tumor microenvironment. Current approaches to meeting this challenge include altering the size, shape, and charge of nanoparticles for easier passage. The main social and legal challenge related to nanomedical treatments is the difficulty of regulating them due to factors such as the near impossibility of detecting nanowaste. Current approaches to meeting this challenge include the use of techniques such as scanning tunneling microscopy and atomic force microscopy to help distinguish nanowaste from the surroundings. More research will have to be done in these and other areas to enhance a major cancer-fighting tool.
ContributorsAbraham, Alfred Francy (Author) / Brian, Jennifer (Thesis director) / Liu, Yan (Committee member) / Materials Science and Engineering Program (Contributor) / Barrett, The Honors College (Contributor)
Created2021-05